-+ 0.00%
-+ 0.00%
-+ 0.00%

China Biopharmaceuticals issued a voluntary announcement. The two national-class innovative drugs independently developed by the company's subsidiary, Zhengda Tianqing, have all been included in the breakthrough therapeutic drug procedure by the Drug Evaluation Center of the China National Drug Administration. The two innovative drugs target functional cure and hypoviremia in the treatment of chronic hepatitis B, respectively. Currently, one of the innovative drugs has started phase III clinical trials, and the other is about to enter phase III clinical trials.

Zhitongcaijing·10/27/2026 00:17:03
Listen to the news
China Biopharmaceuticals issued a voluntary announcement. The two national-class innovative drugs independently developed by the company's subsidiary, Zhengda Tianqing, have all been included in the breakthrough therapeutic drug procedure by the Drug Evaluation Center of the China National Drug Administration. The two innovative drugs target functional cure and hypoviremia in the treatment of chronic hepatitis B, respectively. Currently, one of the innovative drugs has started phase III clinical trials, and the other is about to enter phase III clinical trials.